[1]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2017) Cancer Statistics, 2017. CA: A Cancer Journal for Clinicians, 67, 7-30.
https://doi.org/10.3322/caac.21387
|
[2]
|
Chen, W., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132.
https://doi.org/10.3322/caac.21338
|
[3]
|
Fan, L., et al. (2014) Breast Cancer in China. The Lancet Oncology, 15, e279-e289.
https://doi.org/10.1016/S1470-2045(13)70567-9
|
[4]
|
Mirzania, M., et al. (2017) Treatment Outcomes and Clinicopathologic Characteristics of Triple-Negative Breast Cancer: A Report from Cancer Institute of Iran. International Journal of Hematology-Oncology and Stem Cell Research, 11, 37-42.
|
[5]
|
Cortazar, P. and Geyer, C.E. (2015) Pathological Complete Response in Neoadjuvant Treatment of Breast Cancer. Annals of Surgical Oncology, 22, 1441-1446. https://doi.org/10.1245/s10434-015-4404-8
|
[6]
|
Wang, H. and Mao, X. (2020) Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer. Drug Design, Development and Therapy, 14, 2423-2433. https://doi.org/10.2147/DDDT.S253961
|
[7]
|
von Minckwitz, G., et al. (2012) Definition and Impact of Pathologic Complete Response on Prognosis after Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. Journal of Clinical Oncology, 30, 1796-1804.
https://doi.org/10.1200/JCO.2011.38.8595
|
[8]
|
Cortazar, P., et al. (2014) Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis. The Lancet, 384, 164-172. https://doi.org/10.1016/S0140-6736(13)62422-8
|
[9]
|
张蓉, 等. 三阴性乳腺癌含铂类新辅助化疗的研究进展[J]. 中国肿瘤外科杂志, 2016, 8(1): 43-47.
|
[10]
|
杨辉, 江皓. 新辅助TAC化疗对早期乳腺癌患者疗效、细胞免疫功能和Ki-67的影响[J]. 中华全科医学, 2017, 15(4): 555-557+671.
|
[11]
|
张明, 等. 不同新辅助化疗方案对三阴性乳腺癌治疗疗效临床分析[J]. 昆明医科大学学报, 2015, 36(1): 65-68+88.
|
[12]
|
Sikov, W.M., et al. (2015) Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). Journal of Clinical Oncology, 33, 13-21.
https://doi.org/10.1200/JCO.2014.57.0572
|
[13]
|
von Minckwitz, G., et al. (2014) Neoadjuvant Carboplatin in Patients with Triple-Negative and HER2-Positive Early Breast Cancer (GeparSixto; GBG 66): A Randomised Phase 2 Trial. The Lancet Oncology, 15, 747-756.
https://doi.org/10.1016/S1470-2045(14)70160-3
|
[14]
|
Curtis, C., et al. (2012) The Genomic and Transcriptomic Architecture of 2,000 Breast Tumours Reveals Novel Subgroups. Nature, 486, 346-352. https://doi.org/10.1038/nature10983
|
[15]
|
Schmid, P., et al. (2018) Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. The New England Journal of Medicine, 379, 2108-2121. https://doi.org/10.1056/NEJMoa1809615
|
[16]
|
Schmid, P., et al. (2020) Pembrolizumab for Early Triple-Negative Breast Cancer. The New England Journal of Medicine, 382, 810-821. https://doi.org/10.1056/NEJMoa1910549
|
[17]
|
Li, Q.X., et al. (2019) Association of Body Mass and Systemic Immune-Inflammation Indices with Endocrine Therapy Resistance in Luminal Breast Cancers. Journal of International Medical Research, 47, 1936-1947.
https://doi.org/10.1177/0300060519831570
|
[18]
|
Xu, J., et al. (2017) Association of Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio with ER and PR in Breast Cancer Patients and Their Changes after Neoadjuvant Chemotherapy. Clinical and Translational Oncology, 19, 989-996. https://doi.org/10.1007/s12094-017-1630-5
|
[19]
|
Cihan, Y.B., et al. (2014) Lack of Prognostic Value of Blood Parameters in Patients Receiving Adjuvant Radiotherapy for Breast Cancer. Asian Pacific Journal of Cancer Prevention, 15, 4225-4231.
https://doi.org/10.7314/APJCP.2014.15.10.4225
|
[20]
|
张姗, 等. 长链非编码RNA XIST可预测乳腺癌新辅助治疗的敏感性及预后[J]. 肿瘤, 2020, 40(7): 479-487.
|
[21]
|
Ács, B., et al. (2017) Ki-67 as a Controversial Predictive and Prognostic Marker in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Diagnostic Pathology, 12, 20. https://doi.org/10.1186/s13000-017-0608-5
|
[22]
|
Yoshioka, T., et al. (2015) Prognostic Significance of Pathologic Complete Response and Ki67 Expression after Neoadjuvant Chemotherapy in Breast Cancer. Breast Cancer, 22, 185-191. https://doi.org/10.1007/s12282-013-0474-2
|
[23]
|
Yerushalmi, R., et al. (2010) Ki67 in Breast Cancer: Prognostic and Predictive Potential. The Lancet Oncology, 11, 174-183. https://doi.org/10.1016/S1470-2045(09)70262-1
|
[24]
|
Penault-Llorca, F., et al. (2009) Ki67 Expression and Docetaxel Efficacy in Patients with Estrogen Receptor-Positive Breast Cancer. Journal of Clinical Oncology, 27, 2809-2815. https://doi.org/10.1200/JCO.2008.18.2808
|
[25]
|
单宏杰, 等. 三阴性乳腺癌组织胞外HSP90α表达与新辅助化疗预后关系[J]. 中华肿瘤防治杂志, 2020, 27(4): 293-297.
|
[26]
|
Rooney, M.S., et al. (2015) Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity. Cell, 160, 48-61. https://doi.org/10.1016/j.cell.2014.12.033
|
[27]
|
Matsushita, H., et al. (2012) Cancer Exome Analysis Reveals a T-Cell-Dependent Mechanism of Cancer Immunoediting. Nature, 482, 400-404. https://doi.org/10.1038/nature10755
|
[28]
|
Hanna, G.J., et al. (2018) Frameshift Events Predict Anti-PD-1/L1 Response in Head and Neck Cancer. JCI Insight, 3, e98811. https://doi.org/10.1172/jci.insight.98811
|
[29]
|
Goodman, A.M., et al. (2018) Genomic Landscape of Advanced Basal Cell Carcinoma: Implications for Precision Treatment with Targeted and Immune Therapies. Oncoimmunology, 7, e1404217.
https://doi.org/10.1080/2162402X.2017.1404217
|
[30]
|
Johnson, D.B., et al. (2016) Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. Cancer Immunology Research, 4, 959-967. https://doi.org/10.1158/2326-6066.CIR-16-0143
|
[31]
|
Samstein, R.M., et al. (2019) Tumor Mutational Load Predicts Survival after Immunotherapy across Multiple Cancer Types. Nature Genetics, 51, 202-206. https://doi.org/10.1038/s41588-018-0312-8
|
[32]
|
Geiersbach, K.B. and Samowitz, W.S. (2011) Microsatellite Instability and Colorectal Cancer. Archives of Pathology & Laboratory Medicine, 135, 1269-1277. https://doi.org/10.5858/arpa.2011-0035-RA
|
[33]
|
Le, D.T., et al. (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England Journal of Medicine, 372, 2509-2520. https://doi.org/10.1056/NEJMoa1500596
|
[34]
|
Davies, H., et al. (2017) Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency. Cancer Research, 77, 4755-4762. https://doi.org/10.1158/0008-5472.CAN-17-1083
|
[35]
|
Mills, A.M., et al. (2018) The Relationship between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma. The American Journal of Surgical Pathology, 42, 183-191.
https://doi.org/10.1097/PAS.0000000000000949
|
[36]
|
Borghaei, H., et al. (2015) Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 373, 1627-1639. https://doi.org/10.1056/NEJMoa1507643
|
[37]
|
Carbone, D.P., et al. (2017) First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 376, 2415-2426. https://doi.org/10.1056/NEJMoa1613493
|
[38]
|
Adams, S., et al. (2014) Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers from Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. Journal of Clinical Oncology, 32, 2959-2966. https://doi.org/10.1200/JCO.2013.55.0491
|
[39]
|
Dieci, M.V., et al. (2015) Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in Two Phase III Randomized Adjuvant Breast Cancer Trials. Annals of Oncology, 26, 1698-1704. https://doi.org/10.1093/annonc/mdv239
|
[40]
|
Dieci, M.V., et al. (2014) Prognostic Value of Tumor-Infiltrating Lymphocytes on Residual Disease after Primary Chemotherapy for Triple-Negative Breast Cancer: A Retrospective Multicenter Study. Annals of Oncology, 25, 611-618.
https://doi.org/10.1093/annonc/mdt556
|
[41]
|
Leon-Ferre, R.A., et al. (2018) Impact of Histopathology, Tumor-Infiltrating Lymphocytes, and Adjuvant Chemotherapy on Prognosis of Triple-Negative Breast Cancer. Breast Cancer Research and Treatment, 167, 89-99.
https://doi.org/10.1007/s10549-017-4499-7
|
[42]
|
Mahmoud, S.M., et al. (2011) Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer. Journal of Clinical Oncology, 29, 1949-1955. https://doi.org/10.1200/JCO.2010.30.5037
|
[43]
|
Seo, A.N., et al. (2013) Tumour-Infiltrating CD8+ Lymphocytes as an Independent Predictive Factor for Pathological Complete Response to Primary Systemic Therapy in Breast Cancer. British Journal of Cancer, 109, 2705-2713.
https://doi.org/10.1038/bjc.2013.634
|
[44]
|
Pelekanou, V., et al. (2017) Erratum to: Effect of Neoadjuvant Chemotherapy on Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Breast Cancer and Its Clinical Significance. Breast Cancer Research, 19, 109.
https://doi.org/10.1186/s13058-017-0898-2
|
[45]
|
Xue, D., et al. (2018) Role of Regulatory T Cells and CD8(+) T Lymphocytes in the Dissemination of Circulating Tumor Cells in Primary Invasive Breast Cancer. Oncology Letters, 16, 3045-3053. https://doi.org/10.3892/ol.2018.8993
|
[46]
|
Gu-Trantien, C., et al. (2013) CD4+ Follicular Helper T Cell Infiltration Predicts Breast Cancer Survival. Journal of Clinical Investigation, 123, 2873-2892. https://doi.org/10.1172/JCI67428
|
[47]
|
Pedroza-Gonzalez, A., et al. (2011) Thymic Stromal Lymphopoietin Fosters Human Breast Tumor Growth by Promoting Type 2 Inflammation. Journal of Experimental Medicine, 208, 479-490. https://doi.org/10.1084/jem.20102131
|
[48]
|
Syed Khaja, A.S., et al. (2017) Preferential Accumulation of Regulatory T Cells with Highly Immunosuppressive Characteristics in Breast Tumor Microenvironment. Oncotarget, 8, 33159-33171.
https://doi.org/10.18632/oncotarget.16565
|
[49]
|
Shang, B., et al. (2015) Prognostic Value of Tumor-Infiltrating FoxP3+ Regulatory T Cells in Cancers: A Systematic Review and Meta-Analysis. Scientific Reports, 5, Article No. 15179. https://doi.org/10.1038/srep15179
|
[50]
|
Tumeh, P.C., et al. (2014) PD-1 Blockade Induces Responses by Inhibiting Adaptive Immune Resistance. Nature, 515, 568-571. https://doi.org/10.1038/nature13954
|
[51]
|
Ladoire, S., et al. (2008) Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating foxp3+ Regulatory T Cells. Clinical Cancer Research, 14, 2413-2420. https://doi.org/10.1158/1078-0432.CCR-07-4491
|